Annual Securities Report — FY2025
What Shionogi & Co.,Ltd. reported for the period from 2025-04-01 to 2026-03-31.
Filed 2026-06-19View the original on EDINET
How much it says
58Typical
What moved here
36named for the first time
Its own wording
67terms
Which filing this is
37/ 37newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the consolidated fiscal year, revenue increased, reflecting the succession of the JT pharmaceutical business and the acquisitions of Torii Pharmaceutical and Akros, while R&D expenses also rose and investing cash flow represented a substantial outflow. The filing also states that the fiscal 2025 targets for revenue and EBITDA under SHIONOGI's medium-term management plan, STS2030 Revision, were revised.
Komori's summary of this document, not the document's own words.58Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
96
Very detailed
68
Detailed
74
Detailed
62
Detailed
0
Almost nothing
100
Very detailed
0
Almost nothing
55
Typical
60
Detailed
55
Typical
50
Typical
R&D spend1,228億円Money spent making new things.
Cash left over-2,926億円Cash from the business, less what went into equipment.
Spent on equipment312億円Plants, machines — things meant to last.
Employees2,808Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.